FDA to Review Velmanase Alfa for Alpha-Mannosidosi
The FDA has accepted for Priority Review the Biologics License Application (BLA) for velmanase alfa for the treatment of alpha-mannosidosis.
Source: empr.com
Page 6 - Inborn Errors News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Inborn Errors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Inborn Errors Today - Breaking & Trending Today
Chiesi Global Rare Diseases Announces Presentations on Lysosomal Storage Diseases at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
Results from the clinical development programme developed with Protalix BioTherapeutics evaluating pegunigalsidase alfa (PRX-102) an investigational enzyme...
Source: prnewswire.com
Regenxbio Releases Additional Positive Study Data For Its Hunter Syndrome Drug
(RTTNews) - Regenxbio Inc. (RGNX) Wednesday reported additional positive interim data from the Phase I/II/III CAMPSIITE study of its drug candidat...
Source: businessinsider.com
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2022 - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com
This is to seal it as Aeglea BioTherapeutics Inc. (AGLE) shares are up 62.55% from its 52-week low
Aeglea BioTherapeutics Inc. (AGLE) is priced at $0.60 after the most recent trading session. At the very opening of the session, the stock price was $0.54 and reached a high price of $0.61, prior to closing the session it reached the value of $0.52. The stock touched a low price of $0.53.Recently in
Source: investchronicle.com